Evolving Therapeutic Landscape of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapies

The evolution of immunotherapy spans decades but in recent years clinicians have witnessed the remarkable and often miraculous results that have stemmed from harnessing the immune system. The impact has been most profound in the field of hematological and solid malignancies and has changed the treatment algorithm for diseases that historically had dismal clinical outcomes. Although multiple therapeutic agents such as checkpoint inhibitors and monoclonal antibodies have made significant advances in the field of immunology, bispecific antibodies, and chimeric antigen receptor T-cell (CART) therapies specifically engage T-cells and have both shown profound efficacy in multiple diseases. They are also associated with specific side effects that have necessitated developing expertise in the use and administration of these therapies.

The first goal of this topic is to understand evolving data regarding the use of CART therapy and bispecific antibodies in diseases where pre-clinical studies and clinical trials are ongoing, but the therapies are pending approval by regulatory authorities. These include solid malignancies, certain hematological malignancies, and autoimmune conditions. A second goal of the topic is to compare the two treatment modalities as there are diseases where there is regulatory approval for both CART therapy and bispecific antibodies but how to best sequence and utilize these treatments for long term clinical benefit of patients is not fully understood.

We welcome Original Research articles, Review articles, and Mini-Reviews that focus on, but are not limited to the following:

• CART therapy vs. bispecific antibodies in follicular lymphoma
• CART therapy vs. bispecific antibodies in diffuse large B-cell lymphoma
• Immunotherapies in CLL. A focus on CAR-T cells and bispecifics
• Will bispecific replace CAR-T in MCL?
• CAR-T therapy in CNS lymphomas
• CART therapy vs. bispecific antibodies in multiple myeloma.
• Unique toxicities of CAR-T and bispecific in Myeloma and their management
• CART therapy in solid malignancies
• Management of toxicities of CART therapy vs bispecific antibodies
• The role of CART therapy and bispecific antibody in acute lymphoblastic leukemia
• The role of CART therapy and bispecific antibody in acute myeloid leukemia

Keywords: CART therapy, bispecific antibodies, myeloma, lymphoma, leukemia

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.